Middle East respiratory syndrome coronavirus infection medical therapy: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
Treatment of MERS-CoV: Decision Support Tool | url = http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416 }}</ref> | Treatment of MERS-CoV: Decision Support Tool | url = http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416 }}</ref> | ||
==Supportive Care== | ===Supportive Care=== | ||
The supportive medical care aims to minimize as much as possible the damages caused by [[MERS]]. It is divided into 4 categories, according to the clinical status of the patient. These categories include:<ref name=WHO>{{cite web | title = Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do | url = http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf }}</ref> | The supportive medical care aims to minimize as much as possible the damages caused by [[MERS]]. It is divided into 4 categories, according to the clinical status of the patient. These categories include:<ref name=WHO>{{cite web | title = Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do | url = http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf }}</ref> | ||
=== | ====Supportive Management of Primary Infection==== | ||
*Provide [[oxygen]] therapy to patients with severe acute [[respiratory infections]], presenting with [[hypoxemia]] or [[shock]] | |||
*Administer empiric [[antibiotics]] until the diagnosis of MERS-CoV is confirmed | |||
*Administer fluids carefully in patients with severe acute [[respiratory infections]], even in the absence of [[shock]], since volume overload may jeopardize [[oxygenation]] | |||
*Monitor forpossible clinical deterioration of patients with severe acute [[respiratory infections]] | |||
*Avoid high-dose systemic [[corticosteroids]] to prevent side-effects such as opportunistic [[infections]] and [[avascular necrosis]] | |||
====Management of Acute Respiratory Distress Syndrome==== | |||
{{Details|Acute respiratory distress syndrome medical therapy|the management of ARDS}} | {{Details|Acute respiratory distress syndrome medical therapy|the management of ARDS}} | ||
| Line 39: | Line 34: | ||
*Fluid management in [[ARDS]] patients, in the absence of [[shock]], in order to decrease duration of [[mechanical ventilation]] | *Fluid management in [[ARDS]] patients, in the absence of [[shock]], in order to decrease duration of [[mechanical ventilation]] | ||
====Septic Shock==== | ====Management of Septic Shock==== | ||
{{Details|Sepsis medical therapy|the management of septic shock}} | {{Details|Sepsis medical therapy|the management of septic shock}} | ||
Revision as of 14:00, 16 June 2015
|
Middle East Respiratory Syndrome Coronavirus Infection Microchapters |
|
Differentiating Middle East Respiratory Syndrome Coronavirus Infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Middle East respiratory syndrome coronavirus infection medical therapy On the Web |
|
American Roentgen Ray Society Images of Middle East respiratory syndrome coronavirus infection medical therapy |
|
FDA on Middle East respiratory syndrome coronavirus infection medical therapy |
|
CDC on Middle East respiratory syndrome coronavirus infection medical therapy |
|
Middle East respiratory syndrome coronavirus infection medical therapy in the news |
|
Blogs on Middle East respiratory syndrome coronavirus infection medical therapy |
|
Directions to Hospitals Treating Middle East respiratory syndrome coronavirus infection |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
According to the available data, no specific treatment for MERS-CoV infection is currently available. Clinical management includes supportive management of complications and implementation of recommended infection prevention and control measures.[1]
Medical Therapy
According to the International Severe Acute Respiratory & Emerging Infection Consortium from the ISARIC and the Interim Guidance Document from the WHO, supportive medical care is the mainstay of management of MERS-CoV.[2][3]
Supportive Care
The supportive medical care aims to minimize as much as possible the damages caused by MERS. It is divided into 4 categories, according to the clinical status of the patient. These categories include:[2]
Supportive Management of Primary Infection
- Provide oxygen therapy to patients with severe acute respiratory infections, presenting with hypoxemia or shock
- Administer empiric antibiotics until the diagnosis of MERS-CoV is confirmed
- Administer fluids carefully in patients with severe acute respiratory infections, even in the absence of shock, since volume overload may jeopardize oxygenation
- Monitor forpossible clinical deterioration of patients with severe acute respiratory infections
- Avoid high-dose systemic corticosteroids to prevent side-effects such as opportunistic infections and avascular necrosis
Management of Acute Respiratory Distress Syndrome
This section focuses on management of patients who deteriorate and develop ARDS. It includes:[2]
- Recognition of severe cases where oxygen therapy may not be enough and a higher flow system may be required
- Mechanical ventilation in patients with respiratory distress or hypoxemia that does not resolve with high-flow oxygen therapy
- Non-invasive ventilation (NIV) in cases of immunosuppression or in ARDS that does not present with lack of consciousness or cardiac failure, under constant monitoring in an ICU environment. It is important not to delay endotracheal intubation if NIV is unsuccessful.
- Endotracheal intubation for mechanical ventilation
- In patients with ARDS, use of a lung-protective ventilation with a low pressure ventilation protocol, has shown to reduce mortality in ARDS patients[4][5]
- Adjunctive therapeutics in patients with severe ARDS particularly if ventilation targets are not achieved, such as neuromuscular blockage or repositioning the patient to a prone position[6][7]
- Fluid management in ARDS patients, in the absence of shock, in order to decrease duration of mechanical ventilation
Management of Septic Shock
This section targets the adequate management of septic shock. It includes:[2]
- Recognition of septic shock in the presence of persistent hypotension after fluid administration or signs of peripheral hypoperfusion, followed by resuscitation
- Administration of intravenous crystalloids in septic shock
- In persistent shock it is recommended the use of:
- vasopressors, such as norepinephrine, epinephrine and dopamine, preferably through a central venous catheter and at minimal dosage to insure an SBP >90 mmHg
- need for concomitant IV hydrocortisone (<200 mg/day) or prednisolone (<75 mg/day) administration should be assessed
Prevention of Complications
This section is mainly based on preventing possible complications. It includes:[2]
- Reduction of the period under invasive ventilation, by daily evaluation of spontaneous breathing and titration of sedation to a specific target
- Prevent ventilator-related pneumonia by:
- preferring oral intubation
- performing frequent antiseptic oral care
- adjusting the patient to a reclined position
- preferring a closed suctioning system
- changing the ventilator circuit for every patient
- monitoring the status of heat moisture exchanger
- reducing intermittent mandatory ventilation
- Prevention of venous thromboembolism with pharmacological prophylaxis, in the absence of contraindications. If contraindications are present, it is suggested the prophylactic use of a mechanical device for pneumatic compression
- Prevention of infection through catheter manipulation[8]
- Avoid prolonged immobilization by turning the patient every 2 hours
- Reduce formation of gastric ulcers by administration of early enteric nutrition along with an Histamine H2 receptor blocker or a PPI
- Reduce weakness by immobilization
References
- ↑ "People Who May Be at Increased Risk for MERS".
- ↑ 2.0 2.1 2.2 2.3 2.4 "Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do" (PDF).
- ↑ "Treatment of MERS-CoV: Decision Support Tool".
- ↑ "NIH NHLBI ARDS Clinical Network Mechanical Ventilation Protocol Summary" (PDF).
- ↑ Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM; et al. (2013). "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012". Crit Care Med. 41 (2): 580–637. doi:10.1097/CCM.0b013e31827e83af. PMID 23353941.
- ↑ Papazian, Laurent; Forel, Jean-Marie; Gacouin, Arnaud; Penot-Ragon, Christine; Perrin, Gilles; Loundou, Anderson; Jaber, Samir; Arnal, Jean-Michel; Perez, Didier; Seghboyan, Jean-Marie; Constantin, Jean-Michel; Courant, Pierre; Lefrant, Jean-Yves; Guérin, Claude; Prat, Gwenaël; Morange, Sophie; Roch, Antoine (2010). "Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome". New England Journal of Medicine. 363 (12): 1107–1116. doi:10.1056/NEJMoa1005372. ISSN 0028-4793.
- ↑ Messerole E, Peine P, Wittkopp S, Marini JJ, Albert RK (2002). "The pragmatics of prone positioning". Am J Respir Crit Care Med. 165 (10): 1359–63. doi:10.1164/rccm.2107005. PMID 12016096.
- ↑ Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S; et al. (2006). "An intervention to decrease catheter-related bloodstream infections in the ICU". N Engl J Med. 355 (26): 2725–32. doi:10.1056/NEJMoa061115. PMID 17192537.